SAN DIEGO, May 22, 2017 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that it has been awarded U.S. Patent No. 9671407, entitled DEVICES AND METHODS OF CELL CAPTURE AND ANALYSIS. The patent covers the broad use of antibodies for the capture of any target of interest on any solid surface from any sample type. Targets of interest include, but are not limited to, circulating tumor cells (CTCs), sub-cellular vesicles, and exosomes shed by solid tumors into the
Biocept now has 20 issued patents in the U.S. and key international territories. The newly issued patent complements the Company's intellectual property around its proprietary microchannel platform for the ability to capture and interrogate a wide range of biologic targets of interest.
"The granting of this patent significantly expands Biocept's intellectual property rights regarding the use of 'cocktails' of antibodies for the capture of any target of interest," said Lyle Arnold, Ph.D., Chief Scientific Officer at Biocept. "The expansion of this platform complements nicely with Biocept's circulating tumor DNA (ctDNA) platform and allows us to provide an expanded set of biomarker content to aid physicians in making optimal treatment decisions for their cancer patients."
Michael Nall, Biocept's President and CEO, added, "Obtaining new intellectual property distinguishes our platform's unique and novel features and, in this case, we believe it offers the potential to drive additional value given the broad implications of this patent. We continue to execute on our business plan, as we leverage our proprietary liquid biopsy technology to help physicians obtain actionable biomarker information to improve treatment pathways and patient outcomes."
Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company uses its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. The Company's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in circulating tumor DNA (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options. For additional information, please visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This news release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to be correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend" or "project," or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this news release are not strictly historical, including, without limitation, statements as to our ability to improve the outcomes of cancer patients, the utility and effectiveness of our
intellectual property protections, and our ability to drive additional value of the Company, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this news release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC at www.sec.gov.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biocept-awarded-us-patent-with-broad-claims-for-antibody-capture-of-targets-of-interest-on-any-solid-surface-including-ctcs-and-other-materials-shed-by-solid-tumors-into-blood-300461151.html
SOURCE Biocept, Inc.